Sarepta Therapeutics’ (SRPT) Outperform Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Monday morning, Benzinga reports. They currently have a $182.00 price objective on the biotechnology company’s stock.

SRPT has been the subject of several other reports. Leerink Partners upped their price objective on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, June 24th. Barclays decreased their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Piper Sandler lowered their price objective on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Jefferies Financial Group began coverage on Sarepta Therapeutics in a report on Monday. They set a “buy” rating and a $165.00 target price on the stock. Finally, William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $182.95.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $127.31 on Monday. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. The firm has a market cap of $12.03 billion, a P/E ratio of 1,157.36 and a beta of 0.82. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The firm has a 50-day moving average of $129.00 and a 200-day moving average of $132.39.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The firm had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same period last year, the company earned ($0.27) EPS. Sell-side analysts expect that Sarepta Therapeutics will post 1.45 EPS for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of the stock in a transaction dated Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Michael Andrew Chambers purchased 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Several large investors have recently modified their holdings of SRPT. Nordea Investment Management AB grew its stake in shares of Sarepta Therapeutics by 120.6% during the 1st quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock valued at $8,004,000 after purchasing an additional 33,711 shares during the period. Fifth Third Wealth Advisors LLC bought a new stake in Sarepta Therapeutics during the second quarter valued at approximately $607,000. Teachers Retirement System of The State of Kentucky purchased a new stake in Sarepta Therapeutics during the second quarter valued at approximately $4,771,000. Securian Asset Management Inc. bought a new position in Sarepta Therapeutics in the second quarter worth approximately $1,187,000. Finally, Natixis Advisors LLC purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter worth $1,918,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.